Femasys, Medical Electronic Systems for Sperm Analysis Tech

Femasys Inc. is partnering with Medical Electronic Systems LLC (MES) to provide advanced sperm analysis technology through the FemSperm Analysis Kit.

The Analysis Kit completes the FemSperm product family, joining the Setup Kit and Insemination Prep Kit. Together, the three products expand Femasys’ infertility portfolio and, for the first time, enable gynecologists to perform in-office sperm preparation and analysis for use with its first-step infertility treatment, FemaSeed Intratubal Insemination.

“The launch of the FemSperm Analysis Kit advances our mission to deliver innovative reproductive care that is more accessible and affordable for the millions of women facing infertility,” Femasys Founder/CEO Kathy Lee-Sepsick said. “By partnering with MES and branding their advanced solution under our FemSperm product line, we have created a complete turnkey offering that empowers gynecologists to provide FemaSeed in-office infertility treatment previously available only in fertility clinics.”

With the FemSperm product family’s availability, gynecologists can now perform sperm preparation and analysis, enabling them to offer FemaSeed Intratubal Insemination directly within their practices. FemaSeed is a next-generation artificial insemination solution that enhances natural fertilization by delivering sperm precisely to the fallopian tube, the site of conception. FemaSeed offers a safe, accessible, and cost-effective alternative to intrauterine insemination (IUI). In its pivotal trial, FemaSeed achieved more than double the pregnancy rates of IUI in cases of low male sperm count.¹ As an affordable, less invasive, lower-risk option before IVF, FemaSeed is authorized for use in the United States, Europe, the United Kingdom, Canada, Israel, Australia, and New Zealand.

“Our semen analysis technology powers the FemSperm Analysis Kit, delivering accurate, efficient, and standardized assessment of key sperm parameters,” Medical Electronic Systems President Eric Carver stated. “We are thrilled to partner with Femasys to bring our technology to gynecologists as part of a complete, integrated solution that expands access to high-quality infertility care.”

Femasys is a biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women worldwide through its patent-protected portfolio of in-office therapeutic and diagnostic products. As a U.S. manufacturer with global regulatory approvals, Femasys is actively commercializing its product innovations in the United States and key international markets. Femasys’ fertility portfolio includes FemaSeed Intratubal Insemination, a first-step infertility treatment and FemVue, a companion diagnostic for fallopian tube assessment. Published clinical trial data demonstrates FemaSeed is over twice as effective as traditional IUI, with a comparable safety profile, and high patient and practitioner satisfaction.¹

FemBloc permanent birth control is the first and only non-surgical, in-office alternative to centuries-old surgical sterilization that received full regulatory approval in Europe in June of 2025, United Kingdom in August 2025, and New Zealand in September 2025. Commercialization of this convenient and significantly safer approach will be completed through strategic partnerships in select European countries. Alongside FemBloc, the FemChec, diagnostic product provides an ultrasound-based test to confirm procedural success. Published data from initial clinical trials demonstrated compelling effectiveness, five-year safety, and high patient and practitioner satisfaction.² For U.S. Food and Drug Administration (FDA) approval, enrollment in the FINALE pivotal trial is ongoing.

Medical Electronic Systems (MES) develops automated semen analysis solutions, providing advanced equipment to fertility clinics, hospitals, and laboratories worldwide. MES technologies are designed to deliver accurate, efficient, and standardized results in sperm analysis. MES is recognized for introducing the first FDA- and CE-cleared at-home semen analysis solution, the smartphone-based YO Home Sperm Test, bringing laboratory-grade accuracy to consumers and expanding access to male fertility testing.

References
¹ Liu, J. H., Glassner, M., Gracia, C. R., Johnstone, E. B., Schnell, V. L., Thomas, M. A., L. Morrison, Lee-Sepsick, K. (2024). FemaSeed Directional Intratubal Artificial Insemination for Couples with Male-Factor or Unexplained Infertility Associated with Low Male Sperm Count. J Gynecol Reprod Med, 8(2), 01-12. doi: 10.33140/JGRM.08.02.08.
² Liu, J. H., Blumenthal, P. D., Castaño, P. M., Chudnoff, S. C., Gawron, L. M., Johnstone, E. B., Lee-Sepsick, K. (2025). FemBloc Non-Surgical Permanent Contraception for Occlusion of the Fallopian Tubes. J Gynecol Reprod Med, 9(1), 01-12. doi: 10.33140/JGRM.09.01.05.